Home LiteratureArticle Details
PMID: 7555480 Published · ppublish English Clinical Trial Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, U.S. Gov't, P.H.S.

Implementation of treatment protocols in the Diabetes Control and Complications Trial.

Diabetes care ·Vol. 18 ·No. 3 ·1995-03-00 ·Pages 361-76
Abstract

To describe the methods used to implement intensive and conventional therapies in the Diabetes Control and Complications Trial (DCCT) and the metabolic results that occurred with the different treatment regimens. The DCCT was a controlled clinical trial that demonstrated the beneficial effect of intensive therapy on the long-term complications of insulin-dependent diabetes mellitus (IDDM). A total of 1,441 volunteers with IDDM, aged 13-39, from 29 centers in the U.S. and Canada, were randomly assigned to conventional or intensive diabetes therapy. Intensive therapy, which used multiple daily injections (MDI) of insulin ( > or = 3 injections/day) or continuous subcutaneous insulin infusion (CSII), was implemented by a team that included diabetes nurses, dietitians, behavioral experts, and diabetologists. Volunteers in the intensive treatment group could use MDI or CSII, based on patient and clinic preference, and could switch between therapies over the course of the study. The volunteers were followed for a mean of 6.5 years (range 3-9 years). A detailed analysis of implementation of the two treatments indicates that intensive and conventional treatment subjects adhered to their respective insulin injection regimens > 97% of the time. Adherence to other elements of intensive treatment was similarly high and resulted in median HbA1c values between 6.7 and 7.2, compared with 8.7-9.2 with conventional therapy, over the course of the study. Severe hypoglycemia occurred three times more often in intensively treated subjects. Although subjects on intensive treatment were not randomly assigned to MDI or CSII, we compared those subjects who used either of these methods for > or = 90% of the study time. CSII-treated patients maintained a mean HbA1c of 6.8 vs. 7.0 in MDI-treated subjects during the trial (P < 0.05). The frequency of hypoglycemia with coma and seizure and diabetic ketoacidosis was modestly higher with CSII than with MDI. Intensive therapy was implemented successfully in the DCCT. The detailed description herein will serve to facilitate translation of the DCCT results to the clinical setting.

MeSH Terms
Adolescent Adult Age Factors Blood Glucose/metabolism Canada Catheters, Indwelling/adverse effects Diabetes Mellitus/epidemiology Diabetes Mellitus, Type 1/complications,drug therapy Diabetic Ketoacidosis/epidemiology Diet, Diabetic Drug Administration Schedule Energy Intake Equipment Failure/statistics & numerical data Follow-Up Studies Humans Hypoglycemia/epidemiology Insulin/administration & dosage,therapeutic use Insulin Infusion Systems/adverse effects Multicenter Studies as Topic/methods Obesity Patient Compliance Randomized Controlled Trials as Topic/methods Research Design Socioeconomic Factors Time Factors United States Weight Gain
Chemicals
Blood Glucose Insulin
Article Info
Journal
Diabetes care
Abbr.
Diabetes Care
ISSN
0149-5992
Published
1995-03-00
Pages
361-76
Language
English
Region
United States
NLM ID
7805975
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com